This original research article examines the real-world effectiveness of semaglutide and tirzepatide for obesity treatment, focusing on how medication discontinuation impacts weight loss and glycemic control. The retrospective cohort study analyzed electronic health records from a large patient population in Ohio and Florida. It reveals that discontinuation of these pharmacotherapies is common and significantly reduces the average weight reduction and improvement in glycated hemoglobin levels compared to continuous treatment. The findings suggest that maintaining treatment and using higher dosages are crucial for achieving clinically meaningful outcomes.
Audio Overview (Google NotebookLM)
(9 minutes and 20 seconds)
